SCHEMBL2449583

SCHEMBL2449583

Oc1ccccc1C(=NN1CCCCC1)n1ccnc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
KMT2A Q03164 5/20 0.40
POLB P06746 4/20 0.40
ALDH1A1 P00352 3/20 0.40
GAA P10253 3/20 0.40
MEN1 O00255 3/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
ALOX15 P16050 2/20 0.40
IDO1 P14902 1/20 0.40
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
ADRB3 P13945 1/20 0.37
FAAH O00519 1/20 0.34
MGLL Q99685 1/20 0.34
KDM4E B2RXH2 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2449581 1.00 MAPT (0.40) MAPTKMT2APOLBALDH1A1GAA
SCHEMBL2449411 1.00 MAPT (0.40) MAPTKMT2APOLBALDH1A1GAA
SCHEMBL2453069 0.99 IDO1 (0.41) MAPTKMT2APOLBALDH1A1GAA
SCHEMBL2453066 0.99 IDO1 (0.41) MAPTKMT2APOLBALDH1A1GAA
SCHEMBL2456251 0.86 MAPT (0.40) MAPTKMT2APOLBALDH1A1GAA
SCHEMBL2456250 0.86 MAPT (0.40) MAPTKMT2APOLBALDH1A1GAA
SCHEMBL2451785 0.86 MAPT (0.40) MAPTKMT2APOLBALDH1A1GAA
SCHEMBL2454553 0.84 MAPT (0.38) MAPTKMT2AALDH1A1GAAMEN1
SCHEMBL2454555 0.84 MAPT (0.38) MAPTKMT2AALDH1A1GAAMEN1
SCHEMBL2447171 0.83 ADRB2 (0.37) KMT2AALDH1A1ADRB2ADRB1ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022072-B2 Azolylmethylidenehydrazine derivative and use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2011-09-20 US disclosed
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF ARSA, AHR, HRH2 MAPT 4346/4885KMT2A 1190/4885POLB 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.